Additional €5M funding

Amyl Therapeutics receives additional €5M funding to advance therapeutic platform   Investor base strengthened by Mr Evren Ucok joining as new  shareholder and continued support from historical investors  Financing will be used to accelerate development of Amyl ...

Series A PR

Amyl Therapeutics closes €18.3 million Series A financing to develop novel therapies for Amyloidosis Funds will be used to advance amyloid fibrils specific ClariTY technology platform as a potential best-in-class therapy for patients with Amyloidosis Download Press...